101 related articles for article (PubMed ID: 15951470)
1. Effect of hepatic impairment on the multiple-dose pharmacokinetics of ranolazine sustained-release tablets.
Abdallah H; Jerling M
J Clin Pharmacol; 2005 Jul; 45(7):802-9. PubMed ID: 15951470
[TBL] [Abstract][Full Text] [Related]
2. Effect of renal impairment on multiple-dose pharmacokinetics of extended-release ranolazine.
Jerling M; Abdallah H
Clin Pharmacol Ther; 2005 Sep; 78(3):288-97. PubMed ID: 16153399
[TBL] [Abstract][Full Text] [Related]
3. Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects.
Jerling M; Huan BL; Leung K; Chu N; Abdallah H; Hussein Z
J Clin Pharmacol; 2005 Apr; 45(4):422-33. PubMed ID: 15778423
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of prasugrel in subjects with moderate liver disease.
Small DS; Farid NA; Li YG; Ernest CS; Winters KJ; Salazar DE; Payne CD
J Clin Pharm Ther; 2009 Oct; 34(5):575-83. PubMed ID: 19744013
[TBL] [Abstract][Full Text] [Related]
5. Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment.
Kovarik JM; Sabia HD; Figueiredo J; Zimmermann H; Reynolds C; Dilzer SC; Lasseter K; Rordorf C
Clin Pharmacol Ther; 2001 Nov; 70(5):425-30. PubMed ID: 11719728
[TBL] [Abstract][Full Text] [Related]
6. Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites.
Chalon SA; Desager JP; Desante KA; Frye RF; Witcher J; Long AJ; Sauer JM; Golnez JL; Smith BP; Thomasson HR; Horsmans Y
Clin Pharmacol Ther; 2003 Mar; 73(3):178-91. PubMed ID: 12621383
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of intravenous levosimendan and its metabolites in subjects with hepatic impairment.
Puttonen J; Kantele S; Ruck A; Ramela M; Häkkinen S; Kivikko M; Pentikäinen PJ
J Clin Pharmacol; 2008 Apr; 48(4):445-54. PubMed ID: 18303124
[TBL] [Abstract][Full Text] [Related]
8. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults.
Swearingen D; Pennick M; Shojaei A; Lyne A; Fiske K
Clin Ther; 2007 Apr; 29(4):617-25. PubMed ID: 17617285
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers.
Zhao Q; Iyer GR; Verhaeghe T; Truyen L
J Clin Pharmacol; 2002 Apr; 42(4):428-36. PubMed ID: 11936568
[TBL] [Abstract][Full Text] [Related]
10. A single-dose pharmacokinetic study of lasofoxifene in healthy volunteers and subjects with mild and moderate hepatic impairment.
Bramson C; Ouellet D; Roman D; Randinitis E; Gardner MJ
J Clin Pharmacol; 2006 Jan; 46(1):29-36. PubMed ID: 16397281
[TBL] [Abstract][Full Text] [Related]
11. The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase.
Khosravan R; Grabowski BA; Mayer MD; Wu JT; Joseph-Ridge N; Vernillet L
J Clin Pharmacol; 2006 Jan; 46(1):88-102. PubMed ID: 16397288
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of nelfinavir in subjects with hepatic impairment.
Damle B; Hewlett D; Hsyu PH; Becker M; Petersen A
J Clin Pharmacol; 2006 Nov; 46(11):1241-9. PubMed ID: 17050789
[TBL] [Abstract][Full Text] [Related]
13. Ranolazine for the management of coronary artery disease.
Cheng JW
Clin Ther; 2006 Dec; 28(12):1996-2007. PubMed ID: 17296457
[TBL] [Abstract][Full Text] [Related]
14. Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers.
Alkhalidi BA; Tamimi JJ; Salem II; Ibrahim H; Sallam AA
Clin Ther; 2008 Oct; 30(10):1831-43. PubMed ID: 19014838
[TBL] [Abstract][Full Text] [Related]
15. [Optimization of the formulation of ranolazine hydrochloride sustained-release tablet and its pharmacokinetics in dogs].
Li CJ; Yu YL; Yang QM; Li Y; Zhang YH; Wang JY
Yao Xue Xue Bao; 2010 Sep; 45(9):1170-6. PubMed ID: 21351575
[TBL] [Abstract][Full Text] [Related]
16. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects.
Ramael S; De Smedt F; Toublanc N; Otoul C; Boulanger P; Riethuisen JM; Stockis A
Clin Ther; 2006 May; 28(5):734-44. PubMed ID: 16861095
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of long-acting naltrexone in subjects with mild to moderate hepatic impairment.
Turncliff RZ; Dunbar JL; Dong Q; Silverman BL; Ehrich EW; Dilzer SC; Lasseter KC
J Clin Pharmacol; 2005 Nov; 45(11):1259-67. PubMed ID: 16239359
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of pharmacokinetics and safety of ponatinib in subjects with chronic hepatic impairment and matched healthy subjects.
Narasimhan NI; Dorer DJ; Davis J; Turner CD; Marbury TC; Sonnichsen D
Cancer Chemother Pharmacol; 2014 Aug; 74(2):341-8. PubMed ID: 24934866
[TBL] [Abstract][Full Text] [Related]
19. Determination of ranolazine in human plasma by LC-MS/MS and its application in bioequivalence study.
Bhaumik U; Ghosh A; Sarkar AK; Bose A; Selvan PS; Sengupta P; Chakraborty US; Ghosh D; Pal TK
J Pharm Biomed Anal; 2008 Dec; 48(5):1404-10. PubMed ID: 18986788
[TBL] [Abstract][Full Text] [Related]
20. A pharmacokinetic and pharmacodynamic study, in healthy volunteers, of a rapidly absorbed intranasal midazolam formulation.
Wermeling DP; Record KA; Archer SM; Rudy AC
Epilepsy Res; 2009 Feb; 83(2-3):124-32. PubMed ID: 19046855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]